Blood Stem Cell Transplant With Low Dose Chemotherapy for Relapsed Follicular Non-Hodgkin's Lymphoma (BMT CTN 0701)

Completed · Phase 2

Conditions studied: Lymphoma, Non-Hodgkin

In brief

Blood stem cell transplants are one treatment option for people with lymphoma or other types of blood cancers. For this type of treatment, family members or unrelated donors with a similar tissue type usually donate their blood stem cells to the transplant patients. This study will evaluate the effectiveness of a type of blood stem cell transplant that uses lower doses of chemotherapy in people with relapsed follicular non-Hodgkin's lymphoma (NHL).

Key facts

Study ID

NCT00912223

Run by

Medical College of Wisconsin

People needed

65

Starts

2009-04-01

Expected to finish

2016-08-01

Last updated by the study team

2022-12-09

Who can join

Age: 1 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Must have confirmed CD20+ follicle center lymphoma that meets one of the following:
• Histologically confirmed recurrent Revised European American Lymphoma (REAL) Classification CD20+ follicle center lymphoma, follicular grades I and II
• Histologically confirmed World Health Organization (WHO) classification CD20+ follicular lymphoma grades 1, 2, or 3a.
• For either classification, the diffuse component of large cleaved cells (if present) cannot be greater than 50% of cellularity. Patients do not have to express t(14;18) to be eligible.
• Any number of prior regimens (including autologous hematopoietic cell transplantation [HCT]); the most recent prior regimen must have occurred more than 28 days before study entry
• Must demonstrate chemosensitive or radiosensitive disease to most recent prior regimen and meet one of the following criteria:
• Patients in second or subsequent complete remission (CR)
• Patients in first or subsequent partial remission (PR)
• Patients experiencing a relapse that demonstrates a response, as defined as largest nodal mass less than or equal to 3 cm or greater than or equal to 50% reduction in estimated lymph node volume measured as a product of bi-dimensional measurements (see protocol for detailed definition).
• Patients with stable follicular lymphoma are eligible if all lymph node masses are less than or equal to 3 cm and are smaller or unchanged in size to the most recent salvage regimen.
• Patients with human leukocyte antigen (HLA)-matched donors that meet the following criteria:
• 6/6 HLA-matched related donor. HLA typing must be performed by DNA methods for HLA-A and B at intermediate (or higher) resolution, and DRB1 at high resolution. The donor must be willing to donate peripheral blood stem cells and meet institutional criteria for stem cell donation. The donor must be medically eligible to donate stem cells according to individual transplant center criteria; or,
• 8/8 HLA-matched unrelated donor. HLA typing must be performed by DNA methods for HLA-A, B, C, and DRB1 at high resolution. The donor must be willing to donate peripheral blood stem cells and meet National Marrow Donor Program (NMDP) criteria for stem cell donation. The donor must be medically eligible to donate stem cells according to NMDP criteria.
• Patients with adequate organ function, as measured by the following:
• Heart: Left ventricular ejection fraction at rest greater than 45%
• Lungs: Diffusing capacity of the lung for carbon monoxide (DLCO), forced expiratory volume in one second (FEV1), or forced vital capacity (FVC) greater than 50% of predicted (corrected for hemoglobin). For patients in whom pulse oximetry is performed, baseline O2 saturation greater than 85% (when lung function testing cannot be performed due to age restrictions)
• Liver: Bilirubin less than two times the upper limit of normal for age as per local laboratory; alanine aminotransferase (ALT) and aspartate aminotransferase (AST) less than three times the upper limit of normal as per local laboratory
• Kidney: Calculated or measured creatinine clearance greater than or equal to 40 mL/min; if creatinine is greater than or equal to 1.5 mg/dL then 24-hour urine for measured creatinine clearance should be performed.

You may not qualify if…

• Patients in first CR
• Karnofsky performance score less than 70%
• Patients with follicular lymphoma that demonstrates evidence of histologic transformation. In the presence of B symptoms, rapid growth of a single dominant site, or prolonged (> 2 yrs) interval since last tissue diagnosis, investigators are encouraged to consider re-biopsy of nodes prior to enrollment.
• Uncontrolled hypertension
• Uncontrolled bacterial, viral, or fungal infection (i.e., currently taking medication and progression of clinical symptoms)
• Prior cancer, other than resected basal cell carcinoma or treated cervical carcinoma in situ. Cancer treated with curative intent less than 5 years will not be allowed unless approved by the medical monitor or protocol chair. Cancer treated with curative intent greater than 5 years will be allowed.
• Pregnant or breastfeeding
• Seropositive for human immunodeficiency virus (HIV)
• Fertile men or women unwilling to use contraception from the time of initiation of conditioning until 6 months post-transplant
• Prior allogeneic HSCT
• Known anaphylactic reaction to rituximab
• Seropositive for any of the following: HIV ab, hepatitis B sAg or polymerase chain reaction (PCR)+, or hepatitis C ab or PCR+

Where it is running

• City of Hope National Medical Center — Duarte, California, United States
• University of California, San Diego (UCSD) Medical Center — La Jolla, California, United States
• University of California, Davis Medical Center — Sacramento, California, United States
• Stanford Hospital and Clinics — Stanford, California, United States
• University of Florida College of Medicine — Gainesville, Florida, United States
• H. Lee Moffitt Cancer Center — Tampa, Florida, United States
• Rush University Medical Center — Chicago, Illinois, United States
• Dana-Farber Cancer Institute (DFCI)/Brigham & Women's Hospital — Boston, Massachusetts, United States
• Dana-Farber Cancer Institute (DFCI)/Massachusetts General Hospital — Boston, Massachusetts, United States
• University of Minnesota — Minneapolis, Minnesota, United States
• University of Nebraska Medical Center — Omaha, Nebraska, United States
• University of North Carolina Hospital at Chapel Hill — Chapel Hill, North Carolina, United States
• Wake Forest University Health Sciences — Winston-Salem, North Carolina, United States
• University Hospitals of Cleveland/Case Western — Cleveland, Ohio, United States
• Ohio State/Arthur G. James Cancer Hospital — Columbus, Ohio, United States
• University of Oklahoma Medical Center — Oklahoma City, Oklahoma, United States
• Vanderbilt University Medical Center — Nashville, Tennessee, United States
• University of Texas, MD Anderson Cancer Research Center — Houston, Texas, United States
• West Virginia University — Morgantown, West Virginia, United States
• University of Wisconsin Hospital and Clinics — Madison, Wisconsin, United States
• Medical College of Wisconsin — Milwaukee, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.